Sugi Predict

Sugi Predict / Compounds / SCHEMBL2761699

SCHEMBL2761699

SCHEMBL2761699

CC1(C)OC(=O)c2cccc(O)c2O1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 3/20 0.40
▸ ALDH1A1 P00352 6/20 0.40
▸ CYP3A4 P08684 3/20 0.40
▸ CYP1A2 P05177 2/20 0.40
▸ MAOA P21397 2/20 0.39
▸ MAPT P10636 5/20 0.38
▸ LMNA P02545 4/20 0.38
▸ TDP1 Q9NUW8 4/20 0.38
▸ SMN1; SMN2 Q16637 4/20 0.38
▸ HPGD P15428 3/20 0.38
▸ ALOX15 P16050 3/20 0.38
▸ MAPK1 P28482 3/20 0.38
▸ HSD17B10 Q99714 3/20 0.38
▸ TSHR P16473 1/20 0.38
▸ MAOB P27338 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA7 P43166 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15867212 0.79 DAO (0.39) IDO1ALDH1A1CYP3A4CYP1A2MAPT
SCHEMBL21503789 0.78 ALDH1A1 (0.38) IDO1ALDH1A1CYP3A4CYP1A2LMNA
SCHEMBL30694907 0.78 ALDH1A1 (0.38) IDO1ALDH1A1CYP3A4CYP1A2LMNA
SCHEMBL5080247 0.78 CA1 (0.42) IDO1ALDH1A1CYP3A4CYP1A2MAOA
SCHEMBL18089744 0.78 ADORA2A (0.36) ALDH1A1CYP3A4CYP1A2MAOAMAPT
SCHEMBL31359216 0.77 GNG2 (0.37) ALDH1A1CYP3A4CYP1A2MAPTLMNA
SCHEMBL31217575 0.76 MEN1 (0.42) ALDH1A1MAPTLMNASMN1; SMN2MAPK1
SCHEMBL18827349 0.76 PDK2 (0.41) ALDH1A1CYP3A4CYP1A2SMN1; SMN2MAPK1
SCHEMBL15867213 0.75 ALDH1A1 (0.37) ALDH1A1CYP3A4CYP1A2MAPTSMN1; SMN2
SCHEMBL3156898 0.75 ALDH1A1 (0.49) ALDH1A1CYP3A4CYP1A2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3339303-B9 ARYL AND HETEROARYL FUSED LACTAMS PFIZER (US) 2021-07-21 — — EP disclosed
EP-3339303-B9 ARYL AND HETEROARYL FUSED LACTAMS PFIZER (US) 2021-07-21 — — EP disclosed
EP-3339303-B1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER (US) 2020-06-24 — — EP disclosed
EP-3339303-B1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER (US) 2020-06-24 — — EP disclosed
US-10246433-B2 Aryl and heteroaryl fused lactams PFIZER INC. (US) 2019-04-02 — — US disclosed
US-10246433-B2 Aryl and heteroaryl fused lactams PFIZER INC. (US) 2019-04-02 — — US disclosed
US-10206937-B2 Boronic acid derivatives and therapeutic uses thereof QPEX BIOPHARMA, INC. (US) 2019-02-19 — — US disclosed
EP-3339303-A1 ARYL AND HETEROARYL FUSED LACTAMS Pfizer Inc (US) 2018-06-27 — — EP disclosed
EP-3339303-A1 ARYL AND HETEROARYL FUSED LACTAMS Pfizer Inc (US) 2018-06-27 — — EP disclosed
EP-2935238-B1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER (US) 2017-12-27 — — EP disclosed
WO-2014107535-A1 BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF REMPEX PHARMACEUTICALS, INC. (US) 2014-07-10 — — WO disclosed
US-20140194384-A1 BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF QPEX BIOPHARMA, INC. 2014-07-10 — — US disclosed
US-20140179667-A1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER INC. (US) 2014-06-26 — — US disclosed
WO-2014097041-A1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER INC. (US) 2014-06-26 — — WO disclosed
US-20140179667-A1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER INC. (US) 2014-06-26 — — US disclosed
US-20140179667-A1 ARYL AND HETEROARYL FUSED LACTAMS PFIZER INC. (US) 2014-06-26 — — US disclosed
US-8324405-B2 Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors FIBROGEN, INC. (US) 2012-12-04 — — US disclosed
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. 2010-12-30 — — US disclosed
WO-2009100250-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. (US) 2009-08-13 — — WO disclosed
US-6867200-B1 (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179667-A1 ARYL AND HETEROARYL FUSED LACTAMS CCNY, MLX, NFXL1 IDO1 2679/4885ALDH1A1 2245/4885CYP3A4 498/4885
US-10206937-B2 Boronic acid derivatives and therapeutic uses thereof BCL6B, BTD, BCL6 IDO1 3444/4885ALDH1A1 1999/4885CYP3A4 2433/4885
US-20140194384-A1 BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF BCL6B, BTD, BCL6 IDO1 3444/4885ALDH1A1 1999/4885CYP3A4 2433/4885
US-10246433-B2 Aryl and heteroaryl fused lactams CCNY, MLX, NFXL1 IDO1 2679/4885ALDH1A1 2245/4885CYP3A4 498/4885
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS HIF1AN, HIF1A, EGLN2 IDO1 1414/4885ALDH1A1 202/4885CYP3A4 600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.